Lynparza (chemical name: olaparib) was approved by the U.S. Food and Drug Administration (FDA) on Jan. 12, 2018 to treat metastatic HER2-negative breast cancer with an inherited BRCA1 or BRCA2 mutation that has previously been treated with chemotherapy.
Lynparza is a pill taken by mouth. The recommended starting dose of Lynparza is 300 mg taken twice per day, with or without food.
In this section you can learn more about:
- How Lynparza Works
- Will Lynparza Work for You?
- What to Expect When Taking Lynparza
- Lynparza Side Effects